Research in the ®eld of erectile function and dysfunction is rapidly expanding. Future directions of this research were discussed at the 1st International Consultation on Erectile Dysfunction, held in Paris, July 1999. Important research areas were identi®ed, and some recommendations were made. There is a need for mouse models of erection for molecular biology purposes, and also for new animal models of erectile dysfunction. Behavioral assessments of sexual function are advantageous and deserve to be used more widely. More knowledge about the anatomical interrelations and interactions between different brain nuclei that modulate erection and sexual function is required. Centrally and peripherally, the potential of new neuronal and non-neuronal transmitters and modulators and their interactions should be further explored.
Introduction
Research interest within the ®eld of penile erectile function and dysfunction started to grow with the observations of Virag and Brindley that injection of papaverine and other drugs into the corpora cavernosa produced erection in humans. 1, 2 The report that the nitric oxide (NO) system was involved in erectile mechanisms, 3 and the therapeutic success of sildena®l 4 reinforced this interest. Currently, research on erectile function and dysfunction is being carried out by several research groups specializing in the area.
At the 1st International Consultation on Erectile Dysfunction, held in Paris, July 1999, future directions of research in the ®eld were discussed and recommendations were given. 5 Below are some comments related to the these recommendations.
In vivo models of erection and central neural control
Our knowledge of the physiology of penile erection derives to a great extent from studies performed in animals. It should be remembered that penile erection, which is an integrated part of the complex physiology of male sexual behavior, although highly stereotyped within a species, varies greatly between them. In mammals, penile erection occurs in several different natural contexts, eg, during copulation, as a re¯ex response to stimulation of the genital area, in the presence of an estrous female (contact with the female is not required), and during sleep. To better understand the mechanisms underlying such responses, manipulations of neural and endocrine pathways by pharmacological interventions, lesions, or electrical stimulation of central brain nuclei, have been performed.
Challenges
A challenge today is the search for central and spinal nuclei, neurotransmitters, receptors and second messengers involved in the central control of penile erection. Several hypothalamic areas, such as the medial preoptic area and the paraventricular nucleus, are known sources of descending pathways and represent integrating centers, but other regions contribute and their roles should be established. Not only the anatomical interrelationships, but also the functional interactions among the different brain nuclei that modulate erectile capacity and sexual function needs further exploration. The interactions among the known neurotransmittersamodulators involved in the central regulation of erection are essential areas for future research.
Appropriate models are needed for the study of these areas. Behavioral assessments may be advantageous and should be used more widely. Data collected in studies using animal models of erectile dysfunction should be correlated to clinical studies evaluating erectile dysfunction in humans.
Another challenge is to ®nd out whether one or several peripheral pathways exist between the brain and the penis. This latter aspect gains importance when one considers the impact of peripheral nerve lesions or spinal cord injury on penile erection in patients.
Models
The animals most often used for study are rats, 6 dogs, 7 cats, 8 rabbits 9 and, occasionally, monkeys. 10 Each of these models may have advantages, depending on the aim of the study. Many factors decide which model is the more appropriate, including availability, economy and mechanisms to be studied. However, none or few of the models can be expected to produce results with immediate relevance for humans.
Currently, the rat is probably the most widely used animal for studies of erection. The rat is a suitable model, but there are distinct limitations of the validity for humans of the results obtained. It is, therefore, of utmost importance that this model is well characterized, and that differences in, for example, receptor distribution between human and rat tissues are further studied.
With the development of transgenic mice to evaluate mechanisms of erectile function, it appears particularly advantageous to develop a standardized mouse model of penile erection. Quantitative physiologic experiments on erection may be performed with the mouse as an economical and experimentally advantageous animal model. 11, 12 In vitro preparations and peripheral control of erection
In vitro preparations of different penile tissues, including corpus cavernosum, have been widely used as a tool to understand the local effects of agents supposed to play a role in penile erection. 13 Such tissues are appropriate for the study of transmittersamediators, receptors, ion channels and second messengers.
Challenges
Recent data on previously unknown receptors in penile erectile tissues that, on stimulation, can induce erectile responses are exciting and show that the complex mechanisms involved in penile erection are still far from clari®ed. The potential of new neuronal and non-neuronal transmittersa modulators exempli®ed by adrenomedullin, angiotensin II, and nociceptin should be further investigated. Adrenomedullin is a recently discovered vasodilator peptide isolated from human phaeochromocytoma cells 14 that has structural similarities to calcitonin-gene-related peptide (CGRP). Adrenomedullin has been suggested to serve as a circulating hormone regulating systemic arterial pressure. 14 Champion et al showed that adrenomedullin, injected intracavernously in cats caused an increase in intracavernous pressure and in penile length. 15, 16 The erectile responses to adrenomedullin were unaffected by NO-synthase inhibition with L-NAME, or by K ATP channel inhibition with glibenclamide, suggesting that NO or K ATP channels were not involved in the response. Further studies are needed to clarify the mechanisms and potential clinical usefulness of these observations.
Kifor et al reported that human corpus cavernosum produces and secretes physiologically relevant amounts of angiotensin II. 17 It was also found that, in vitro, angiotensin II contracted canine corpus cavernosum smooth muscle, an effect that was increased by NOS inhibition. 18 Intracavernosal injection of angiotensin II caused contraction and terminated spontaneous erections in anesthetized dogs, whereas administration of losartan, selectively blocking angiotensin II receptors (type AT1), resulted in smooth muscle relaxation and erection. 17 Also, in the rabbit corpus cavernosum, results were obtained suggesting involvement of the renin ± angiotensin system in the regulation of corpus cavernosum smooth muscle tone. 19 Whether or not angiotensin II is an important regulator of tone in penile erectile tissues is unclear, and studies designed to elucidate this question would be of interest.
Nociceptin or Orphanin FQ is a 17 amino-acid peptide that shares structural homology with the dynorphine family of peptides. It differs from other opioid peptides by not having the NH 2 -terminal residue which is essential for activity at m, d, and k opiod receptors. 20, 21 The drug is an endogenous ligand for the OP 4 receptor that has been identi®ed in several species. Its function is not established, but it may be involved in various physiological functions. 20 , 21 Champion et al showed that nociceptin elicited dose-related increases in intracavernous pressure and penile length 22 and this effect was naloxone-resistant. 23 Further studies on the role of the nociceptinaOP 4 system for erection are warranted.
Continued efforts
Among the neurotransmitteratransmitter generating enzymes present in parasympathetic nerve endings (eg, NO, VIP, acetylcholine), NO seems to be the main mediator of penile erection. Both acetylcholine and NO can in¯uence NA release by sympathetic nerve endings, and acetylcholine can facilitate NO release by endothelial cells. The interactions between these different transmittersamodulators in the penis still remain to be elucidated, and may be an important basis for the development of combination therapy.
VIP, whose role in the local mechanisms of penile erection was extensively investigated during the 1980s, has been suggested to play a role in proerectile mechanisms, occurring at a longer latency and displaying a longer effect (eg, vascular tone and adaptation of penile arteries). More evidence is required before this mechanism becomes established.
The presence of several NOS isoforms in the penis was demonstrated by combining measurements of enzyme speci®c activity, immunohistochemistry, protein analysis with Western blot, and mRNA analysis with Northern blot. A variety of experiments converge to provide evidence of the presence of nNOS (neuronal NOS) in the rat penis. 24 Important directions for further investigations are the search for other NOS isoforms in the penis of other animal species. There are also studies using animal models that mimic diseases known to elicit erectile dysfunction in humans (diabetes, hypercholesterolemia, hypertension, atherosclerosis) or natural alteration of erection (aging). In some of these models, an alteration of the NOS functions has been demonstrated. 25 ± 27 Further studies in this direction might be fruitful.
Signal transduction and smooth muscle function
Much of our knowledge on signal transduction and smooth muscle function derives from studies performed on non-penile smooth muscle. The signal pathways for different transmittersamodulators need to be studied in detail in penile erectile tissues. For example the distribution and roles of eg, cyclases, phosphodiesterases, and protein kinases need further study.
cAMP and cGMP are synthetized from the corresponding nucleoside triphosphates by their respective membrane-bound or soluble adenylate or guanylate cyclases. Studies on the distribution, characteristics and function of these cyclases in penile tissues would be of interest. cAMP and cGMP are inactivated by phosphodiesterases (PDEs) by hydrolytic cleavage of the 3 ' -ribose-phosphate bond. Presently, more than nine different families of PDE are known, which differ in their speci®city for cAMP and cGMP, cofactor requirements and kinetic properties. 29, 30 Each family can, in turn, be divided into subfamilies. Because of their central role in smooth-muscle tone regulation and the considerable variation of PDE isoenzymes with respect to species and tissues, PDEs have become an attractive target for drug development. PDE 2, PDE 3, PDE 4, PDE 5 and several other isoenzymes have been identi®ed in human cavernous tissue. 31 ± 35 Functionally, PDE 3 and PDE 5 seem to be the most important, 2, 36 however, details on distribution and functional importance of the different PDEs remain to be established. Selective or partially selective PDE inhibitors are available, and are possible tools to be employed.
Sildena®l is a selective inhibitor of PDE type 5 37, 38 and its main mechanism of action is apparently understood, but many details are still to be elucidated. Chuang et al found that sildena®l ampli®ed the effect of endogenous NO-cyclic GMP by a novel cellular signal transduction pathway in which force is dissociated from myosin light chain phosphorylation. 39 Further studies based on this observation may be rewarding.
Many other areas need to be studied in penile tissue. 5 The cell-to-cell transmission of activation, excitation ± contraction coupling, the distribution and roles of different ion channels, and changes in contractile proteins with erectile dysfunction are all areas where further information is needed.
Therapeutic aspects
As a general aim for therapeutic reseach, strategies to prevent cavernosal degeneration andaor to restore cavernosal function should be explored. More speci®cally, efforts within the areas of somatic gene therapy and drug development should be persued.
Gene therapy and erectile dysfunction
Current experiences in the ®eld of gene therapy may be applied to human erectile tissues, and several approaches have been suggested. 40 ± 44 For example, Future research in erectile dysfunction K-E Andersson since the Ca 2 -sensitive K channel (maxi-K ) seems to be an important modulator of corporal smooth muscle tone, Christ et al transfected corporal smooth muscle cells in vivo with the hSlo cDNA, which encodes for the human smooth muscle maxi-K channel. 42 Electrical stimulation of the cavernous nerve revealed that, relative to the responses obtained in age-matched control animals, intracavernous injection of naked pcDNAahSlo DNA was associated with a statistically signi®cant elevation in the mean amplitude of the intracavernous pressure response at all levels of current stimulation. The data indicated that naked hSlo DNA is quite easily incorporated into corporal smooth muscle and that expression was sustained for at least 2 months in corporal smooth muscle cells in vivo. Finally, after expression, hSlo was capable of measurably altering nerve-stimulated penile erection.
Taken together, the data provided compelling evidence for the potential utility of gene therapy in the treatment of erectile dysfunction.
Another approach was recently described by Champion et al. 43 Since it has been shown that NOS activity decreases with age, they administered a recombinant adenovirus containing the eNOS gene (AdCMVeNOS) into the corpora cavernosum of the aged rat. One day after administration of AdCMVeNOS, transgene expression was con®rmed by immunoblot staining of eNOS protein, and cGMP levels were increased. The increase in cavernosal pressure in response to cavernosal nerve stimulation was enhanced in animals transfected with eNOS, and erectile responses to acetylcholine and zaprinast were enhanced. The results suggested that in vivo gene transfer of eNOS, alone or in combination with a type 5 PDE inhibitor, may constitute a new therapeutic intervention for the treatment of erectile dysfunction. Continued efforts in this area of research may lead to a break-through in the treatment of erectile dysfunction.
Pharmacological basis for future therapies
It is reasonable to expect that the studies on basal mechanisms (transmittersamodulators, signalling pathways etc) will de®ne new molecular targets for drug treatment. The development of drugs based on such observations is an important research direction.
Since erectile dysfunction may be a multifactorial disease, future therapies may include combinations of different drug principles. Studies aimed at establishing which drug combinations are necessary for optimizing treatment are important and should be carried out.
Conclusions
Knowledge within the ®eld of erectile physiology and pathophysiology has increased dramatically during the last decade. Much of the new information generated has been the basis for the therapeutic progress achieved during this period. New, potentially useful therapeutic mechanisms remain to be be investigated, and the application of gene therapy might produce a new break-through for the treatment of erectile dysfunction. 16 
